Miscellaneous Urogenital Disorders
A Phase 3 trial (Vista) of the treatment is currently taking place; the trial is evaluating the treatment in patients with NMIBC who have previously received 2 courses of BCG and who are now BCG-unresponsive.
The researchers found that stone passage rates were 50% in the tamsulosin group and 47% in the placebo group (relative risk, 1.05; 95.8% confidence interval, 0.87 to 1.27; P=.60).
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Time-dependent metformin use was not associated with incident acidosis overall or in those with eGFR 45 to 59 and 30 to 44 mL/min/1.73 m² (aHR, 1.16 [95% CI, 0.95 to 1.41] and 1.09 [95% CI, 0.83 to 1.44]) compared with alternative diabetes management.
However, there was no significant difference in visceral fat area (P=.32), subcutaneous fat area (P=.36), visceral fat volume (P=.38), or subcutaneous fat volume (P=.23).
"The VFI-based approach allows for the rapid determination of mGFR at the bedside while maintaining patient safety and measurement accuracy and reproducibility," the authors write.
In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
Over the study period, compared with non-smoking throughout follow-up, the multivariable-adjusted hazard ratios were 1.02 (95% confidence interval [CI], 0.86 to 1.21) for CKD progression and 1.86 (95% CI, 1.54 to 2.24) for all-cause mortality for persistent tobacco smoking.
To evaluate safety and efficacy of this therapy, study authors gathered data on patients treated with the combination from 2014 to 2017.
After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
Data Monitoring Committees (DMC) from two ongoing clinical trials (KEYNOTE-361 and IMVIGOR-130) found that in the monotherapy arms of these studies, patients with low PD-L1 status had decreased survival compared with those who received cisplatin- or carboplatin-based chemotherapy.
AKI was independently associated with higher rates of the composite outcome of hospitalization for heart failure and atherosclerotic events 1-year post-discharge.
Acetaminophen exposure was protective against postoperative AKI after adjustment for multiple confounding variables (odds ratio, 0.86 per each additional 10mg/kg).
In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls.
In patients with glomerular filtration rate (GFR) ≥45 mL/min/1.73 m² there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until 1 year.
The strength of these associations was greatest for exposures at younger ages (P<.001) and 3 to 6 months before the index date (P<.001), with all but broad-spectrum penicillins remaining statistically significant 3 to 5 years from exposure.
In this randomized controlled trial, coaching to improve daily fluid intake did not improve kidney function in patients with Chronic Kidney Disease.
Forty percent indicated that they were currently sexually active; sexual activity decreased with age. More than half (54%) of respondents agreed that sex is important to their overall quality of life, with men more likely to agree than women (70 versus 40%).
There was a correlation for opioid use with risk for all outcomes in a dose-dependent manner: altered mental status, fall, and fracture.
"CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children," the authors write.
The researchers found that AKI occurred in 18.1% of neonates in the first seven days after birth and occurred less frequently among neonates who received caffeine versus those who did not (11.2 versus 31.6%; P<0.01).
Time from referral to waitlisting was 126 days longer for intervention patients. While there was no difference in waitlisting in the early period between intervention and control patients (hazard ratio, 1.03; 95% confidence interval, 0.69 to 1.53), intervention patients were 3.3 times more likely to be waitlisted after 500 days.